814 research outputs found
Properties of Factorial Cumulant to Factorial Moment Ratio
It is shown that the ratio of factorial cumulant moments to factorial moments
for a multiplicity distribution truncated in the tail reveals oscillations in
sign similar to those observed in experimental data. It is suggested that this
effect be taken into account in the analysis of data in order to obtain correct
physical information on the multiplicity distributions.Comment: (LaTeX + epsfig, 8 pages including 3 PostScript figures, all encoded
via uufiles), DFTT 46/9
Clan Properties in Parton Showers
By considering clans as genuine elementary subprocesses, i.e., intermediate
parton sources in the Simplified Parton Shower model, a generalized version of
this model is defined. It predicts analytically clan properties at parton level
in agreement with the general trends observed experimentally at hadronic level
and in Monte Carlo simulations both at partonic and hadronic level. In
particular the model shows a linear rising in rapidity of the average number of
clans at fixed energy of the initial parton and its subsequent bending for
rapidity intervals at the border of phase space, and approximate energy
independence of the average number of clans in fixed rapidity intervals. The
energy independence becomes stricter by properly normalizing the average number
of clans.Comment: (27 pages in Plain TeX plus 10 Postscript Figures, all compressed via
uufiles) DFTT 7/9
Clan Structure in Rapidity Intervals
We present a cascading model for a single jet, inspired to QCD and to the
phenomenological analysis of multiplicity distributions. The model, describing
as it does a two dimensional evolution in virtuality and rapidity, allows
analytical predictions for clan analysis parameters to be made.Comment: Talk presented by R. Ugoccioni at XXV Multiparticle Dynamics, Stara
Lesna, Slovakia, Sept. 1995. LaTeX with epsfig, 11 pages, 3 figures.
Postscript file available through
http://www.thep.lu.se/tf2/hep/article.hep.htm
Maps of zeroes of the grand canonical partition function in a statistical model of high energy collisions
Theorems on zeroes of the truncated generating function in the complex plane
are reviewed. When examined in the framework of a statistical model of high
energy collisions based on the negative binomial (Pascal) multiplicity
distribution, these results lead to maps of zeroes of the grand canonical
partition function which allow to interpret in a novel way different classes of
events in pp collisions at LHC c.m. energies.Comment: 17 pages, figures (ps included); added references, some figures
enlarged. To appear in J. Phys.
Is there a role for dual PI3K/mTOR inhibitors for patients affected with lymphoma?
The activation of the PI3K/AKT/mTOR pathway is a main driver of cell growth, proliferation, survival, and chemoresistance of cancer cells, and, for this reason, represents an attractive target for developing targeted anti-cancer drugs. There are plenty of preclinical data sustaining the anti-tumor activity of dual PI3K/mTOR inhibitors as single agents and in combination in lymphomas. Clinical responses, including complete remissions (especially in follicular lymphoma patients), are also observed in the very few clinical studies performed in patients that are affected by relapsed/refractory lymphomas or chronic lymphocytic leukemia. In this review, we summarize the literature on dual PI3K/mTOR inhibitors focusing on the lymphoma setting, presenting both the three compounds still in clinical development and those with a clinical program stopped or put on hold
Inside perspective of the synthetic and computational toolbox of JAK inhibitors: Recent updates
The mechanisms of inflammation and cancer are intertwined by complex networks of signaling pathways. Dysregulations in the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway underlie several pathogenic conditions related to chronic inflammatory states, autoimmune diseases and cancer. Historically, the potential application of JAK inhibition has been thoroughly explored, thus triggering an escalation of favorable results in this field. So far, five JAK inhibitors have been approved by the Food and Drug Administration (FDA) for the treatment of different diseases. Considering the complexity of JAK-depending processes and their involvement in multiple disorders, JAK inhibitors are the perfect candidates for drug repurposing and for the assessment of multitarget strategies. Herein we reviewed the recent progress concerning JAK inhibition, including the innovations provided by the release of JAKs crystal structures and the improvement of synthetic strategies aimed to simplify of the industrial scale-up
- …